Chronic Lymphocytic Leukemia News

This RSS feed URL is deprecated


This RSS feed URL is deprecated, please update. New URLs can be found in the footers at https://news.google.com/news

Study shows combining chemotherapy with targeted drug boosts response in chronic lymphocytic leukemia - EurekAlert (press release)



OncLive
 
Study shows combining chemotherapy with targeted drug boosts response in chronic lymphocytic leukemia 
EurekAlert (press release)
ATLANTA - Among younger patients newly diagnosed with chronic lymphocytic leukemia (CLL), treatment with a combination of chemotherapy and a molecularly targeted drug significantly improves response over what is typically seen with chemotherapy alone ...
Study explores use of checkpoint inhibitors after relapse from donor stem cell transplant Medical Xpress
Dr. Davids on Checkpoint Blockade Inhibition in Hematologic ... OncLive

all 9 news articles » 


(acalabrutinib) Shows Potential in Chronic Lymphocytic Leukemia Trials - Business Wire (press release)



(acalabrutinib) Shows Potential in Chronic Lymphocytic Leukemia Trials 
Business Wire (press release)
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca and Acerta Pharma, its hematology research and development center of excellence, today presented results from the Phase Ib/II ACE-CL-003 clinical trial (Abstract #432) and updated results from the Phase I ...

and more » 


Single-Agent Ibrutinib Promising in MCL and CLL, Improves Patient Well-Being - AJMC.com Managed Markets Network



OncLive
 
Single-Agent Ibrutinib Promising in MCL and CLL, Improves Patient Well-Being 
AJMC.com Managed Markets Network
Single-agent ibrutinib vs chemoimmunotherapy regimens for treatment-na´ve patients with chronic lymphocytic leukemia (cll): a cross-trial comparison. In: Proceedings from the 59th Annual Meeting and Exposition of the American Society of Hematology ...
Ibrutinib/Venetoclax Combo Impresses in Early CLL Data OncLive
Combination Ibrutinib/Venetoclax Shows Early Promise in Previously Treated CLL Cancer Network
Combo Treatment Offers New Hope in Tough-to-Treat CLL MedPage Today

all 5 news articles » 


Verastem Announces Clinical Data from the Pivotal Phase 3 DUO? Study: Duvelisib Significantly Improves ... - Business Wire (press release)



Endpoints News
 
Verastem Announces Clinical Data from the Pivotal Phase 3 DUO? Study: Duvelisib Significantly Improves ... 
Business Wire (press release)
BOSTON--(BUSINESS WIRE)--Verastem, Inc. (NASDAQ: VSTM), focused on discovering and developing drugs to improve the survival and quality of life of cancer patients, today announced the presentation of the results from the Phase 3 DUO study evaluating ...
#ASH17: Verastem's AbbVie castoff is headed for the FDA ? even after missing overall survival goal Endpoints News

all 2 news articles » 


Fisheries Minister Dominic LeBlanc Diagnosed With Chronic Lymphocytic Leukemia - Huffington Post Canada



Huffington Post Canada
 
Fisheries Minister Dominic LeBlanc Diagnosed With Chronic Lymphocytic Leukemia 
Huffington Post Canada
The release also quotes specialist Dr. Nicholas Finn saying LeBlanc's cancer is one of the most common types of leukemia in adults. "CLL is a chronic disease in the sense that it must be closely monitored and sometimes treated, but can be controlled ...
Dominic LeBlanc, federal fisheries minister, diagnosed with leukemia Globalnews.ca
Fisheries Minister Dominic LeBlanc diagnosed with leukemia Hill Times
Federal Fisheries Minister Dominic LeBlanc diagnosed with ... CBC.ca
Surrey Now-Leader  -Markets Insider 
all 17 news articles » 


CURE Media Group Partners with the Chronic Lymphocytic ... - Business Wire (press release)



CURE Media Group Partners with the Chronic Lymphocytic ... 
Business Wire (press release)
CRANBURY, N.J.--(BUSINESS WIRE)--CURE Media Group, the nation's leading digital and print media enterprise dedicated to patients with cancer, has added The CLL Society, which serves the Chronic Lymphocytic Leukemia community, to its Strategic Alliance ...

and more » 


Verastem to Present Results from Pivotal Phase 3 DUO Study in ... - Business Wire (press release)



Verastem to Present Results from Pivotal Phase 3 DUO Study in ... 
Business Wire (press release)
BOSTON--(BUSINESS WIRE)--Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to improve the survival and quality of life of cancer patients, will present clinical data from the Phase 3 DUO study evaluating the efficacy and safety ...

and more » 


Survey Helps Doctors Better Understand Therapy Choices by Chronic Lymphocytic Leukemia Patients - Lymphoma News Today



Survey Helps Doctors Better Understand Therapy Choices by Chronic Lymphocytic Leukemia Patients 
Lymphoma News Today
A survey of patients with chronic lymphocytic leukemia (CLL) about multiple treatment scenarios found that while their top priority is longest progression-free survival, they are willing to make sacrifices on a therapy's effectiveness if it reduces or ...

 


Dr. Rogers Discusses Early Intervention With Ibrutinib in CLL - OncLive



OncLive
 
Dr. Rogers Discusses Early Intervention With Ibrutinib in CLL 
OncLive
Kerry Rogers, MD, Assistant Professor, Internal Medicine, Division of Hematology, The Ohio State University Comprehensive Cancer Center, discusses a phase II trial of early intervention with ibrutinib (Imbruvica) in patients with asymptomatic, high ...

and more » 


BeiGene Presents Updated Preliminary Phase 1b Data on BTK Inhibitor Zanubrutinib (BGB-3111) Combined with ... - GlobeNewswire (press release)



BeiGene Presents Updated Preliminary Phase 1b Data on BTK Inhibitor Zanubrutinib (BGB-3111) Combined with ... 
GlobeNewswire (press release)
?These updated Phase 1b data continue to indicate that zanubrutinib in combination with obinutuzumab is well tolerated and highly active in patients with CLL/SLL and FL. Toxicity-related treatment discontinuation has been rare, and the rate and depth ...